Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 11/20 | 0.43 |
| ▸ | CDK9 | P50750 | 11/20 | 0.43 |
| ▸ | CDK2 | P24941 | 8/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538339 | 0.91 | CCNT1 (0.49) | CCNT1CDK9CDK2CDK4CDK1 | |
| SCHEMBL2541901 | 0.86 | PLK1 (0.43) | CCNT1CDK9CDK2CDK4CDK1 | |
| SCHEMBL2544634 | 0.85 | IKBKB (0.55) | CDK2CCNE1IKBKB | |
| SCHEMBL2539825 | 0.84 | CDK1 (0.53) | CCNT1CDK9CDK2CDK1CCNB1 | |
| SCHEMBL2547332 | 0.81 | JAK2 (0.53) | CCNT1CDK9CDK2CDK4CDK1 | |
| SCHEMBL15085752 | 0.81 | CDK2 (0.48) | CCNT1CDK9CDK2CDK4CDK1 | |
| SCHEMBL2542192 | 0.80 | PLK1 (0.48) | CCNT1CDK9CDK2CDK4CDK1 | |
| SCHEMBL2539545 | 0.80 | ACVR1 (0.49) | CCNT1CDK9CDK2CDK4CDK1 | |
| SCHEMBL2542799 | 0.80 | FLT3 (0.55) | CDK9CDK2CDK4CDK1CCNB1 | |
| SCHEMBL2543307 | 0.79 | CCNT1 (0.54) | CCNT1CDK9CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | CCNT1 2891/4885CDK9 825/4885CDK2 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.